Search for dissertations about: "Rivaroxaban"

Showing result 1 - 5 of 6 swedish dissertations containing the word Rivaroxaban.

  2. 1. Venous thromboembolism: Risk factors, comorbidities, and treatment-associated risk of bleedings

    Author : Katarina Glise Sandblad; Göteborgs universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Venous thromboembolism; Registries; Overweight; Body mass index; Incidence; Cardiovascular disease; Anticoagulants; Apixaban; Rivaroxaban; Warfarin; Hemorrhage;

    Abstract : Background: Venous thromboembolism (VTE) is the third most common cardiovascular disease, consisting mainly of deep vein thrombosis (DVT) and pulmonary embolism (PE). Since VTE often is a preventable disease, knowledge of risk factors is critical. Following a VTE, many patients are subjected to extended anticoagulant treatment. READ MORE

  4. 2. Oral anticoagulation and stroke risk

    Author : Vilhelm Sjögren; Anders Själander; Per Wester; Peter J Svensson; Mia von Euler; Umeå universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Stroke; warfarin; atrial fibrillation; dabigatran; rivaroxaban; apixaban; low-molecular-weight heparin; bridging;

    Abstract : Background: The risk of ischaemic stroke in patients with atrial fibrillation (AF) and mechanical heart valve (MHV) prostheses can be reduced by oral anticoagulation (OAC), which increases the risk of serious bleeding. The aims of this thesis were [1] to find out how effective and safe warfarin is where treatment quality is high, i.e. READ MORE

  5. 3. Monitoring of the oral anticoagulants apixaban and rivaroxaban to optimize individual safety and efficacy

    Author : Fadiea Al-Aieshy; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : The oral anticoagulants apixaban and rivaroxaban are administered at fixed doses without requiring routine monitoring. However, there is a dose and exposure dependency in efficacy and safety, and monitoring the anticoagulants may improve treatment outcomes. READ MORE

  6. 4. Antithrombotic treatment of atrial fibrillation before and after the introduction of non-vitamin K antagonist oral anticoagulants (NOAC) in the Stockholm health care region

    Author : Tomas Forslund; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : Atrial fibrillation (AF) is the most common cardiac arrhythmia and the major risk factor for thromboembolic stroke. Effective treatment with the oral anticoagulant (OAC) warfarin has been available for decades. However warfarin treatment is complicated, and demands dose adjustments and regular monitoring. READ MORE

  7. 5. Effects of direct oral anticoagulant treatment on hemostasis in patients with atrial fibrillation

    Author : Viktor Schutz Taune; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : The direct oral anticoagulants (DOAC) – dabigatran, rivaroxaban, apixaban and edoxaban – were approved without the need for routine monitoring. However, in parallel with clinical implementation, studies on how to measure the effect of DOACs have become a research area of increasing interest during the last decade. READ MORE